Neogen Corporation Cost of Revenue
Neogen Corporation (NEOG) reported Cost of Revenue of $461.90 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-30
- Neogen Corporation cost of goods and services sold for the quarter ending 2026-05-31 was $117.50M, a 11.39% decline year-over-year.
- Neogen Corporation cost of goods and services sold for the quarter ending 2026-02-28 was $112.20M, a 1.36% increase year-over-year.
- Neogen Corporation cost of goods and services sold for the quarter ending 2025-11-30 was $118.01M, a 0.07% increase year-over-year.
- Neogen Corporation cost of goods and services sold for the quarter ending 2025-08-31 was $114.22M, a 1.95% increase year-over-year.
- Neogen Corporation cost of goods and services sold for fiscal 2026 was $461.90M, a 2.41% decline from fiscal 2025.
- Neogen Corporation cost of goods and services sold for fiscal 2025 was $473.30M, a 2.82% increase from fiscal 2024.
- Neogen Corporation cost of goods and services sold for fiscal 2024 was $460.30M, a 10.52% increase from fiscal 2023.
- Neogen Corporation cost of goods and services sold for fiscal 2023 was $416.49M, a 46.58% increase from fiscal 2022.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-05-31 | $117.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $229.70M derived: sum of 2 quarters · filed 2026-07-30 | $347.71M derived: sum of 3 quarters · filed 2026-07-30 | $461.90M 10-K · filed 2026-07-30 | |||
| 2026-02-28 | $112.20M 10-Q · filed 2026-04-09 | $230.21M derived: sum of 2 quarters · filed 2026-04-09 | $344.40M 10-Q · filed 2026-04-09 | $477.03M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-11-30 | $118.01M 10-Q · filed 2026-01-08 | $232.23M 10-Q · filed 2026-01-08 | $364.83M derived: sum of 3 quarters · filed 2026-07-30 | $475.53M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-08-31 | $114.22M 10-Q · filed 2025-10-09 | $246.82M derived: sum of 2 quarters · filed 2026-07-30 | $357.52M derived: sum of 3 quarters · filed 2026-07-30 | $475.45M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-05-31 | $132.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $243.30M derived: sum of 2 quarters · filed 2026-07-30 | $361.23M derived: sum of 3 quarters · filed 2026-07-30 | $473.30M 10-K · filed 2026-07-30 | $473.29M 10-K · filed 2025-07-30 | ||
| 2025-02-28 | $110.70M 10-Q · filed 2026-04-09 | $110.72M 10-Q · filed 2025-04-09 | $228.63M derived: sum of 2 quarters · filed 2026-04-09 | $340.70M 10-Q · filed 2026-04-09 | $340.68M 10-Q · filed 2025-04-09 | $463.96M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2024-11-30 | $117.93M 10-Q · filed 2026-01-08 | $229.97M 10-Q · filed 2026-01-08 | $353.26M derived: sum of 3 quarters · filed 2026-07-30 | $465.19M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2024-08-31 | $112.04M 10-Q · filed 2025-10-09 | $235.33M derived: sum of 2 quarters · filed 2026-07-30 | $347.26M derived: sum of 3 quarters · filed 2026-07-30 | $460.11M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2024-05-31 | $123.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $235.22M derived: sum of 2 quarters · filed 2026-07-30 | $348.07M derived: sum of 3 quarters · filed 2026-07-30 | $460.30M 10-K · filed 2026-07-30 | $460.32M 10-K · filed 2024-07-30 | ||
| 2024-02-29 | $111.93M 10-Q · filed 2025-04-09 | $224.78M derived: sum of 2 quarters · filed 2025-04-09 | $337.01M 10-Q · filed 2025-04-09 | $455.64M derived: sum of 4 quarters · filed 2025-07-30 | |||
| 2023-11-30 | $112.86M 10-Q · filed 2025-01-15 | $225.08M 10-Q · filed 2025-01-15 | $343.71M derived: sum of 3 quarters · filed 2025-07-30 | $454.00M derived: sum of 4 quarters · filed 2025-07-30 | |||
| 2023-08-31 | $112.23M 10-Q · filed 2024-10-10 | $230.85M derived: sum of 2 quarters · filed 2025-07-30 | $341.14M derived: sum of 3 quarters · filed 2025-07-30 | $458.64M derived: sum of 4 quarters · filed 2025-07-30 | |||
| 2023-05-31 | $118.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-30 | $228.92M derived: sum of 2 quarters · filed 2025-07-30 | $346.41M derived: sum of 3 quarters · filed 2025-07-30 | $416.49M 10-K · filed 2025-07-30 | |||
| 2023-02-28 | $110.29M 10-Q · filed 2024-04-09 | $227.78M derived: sum of 2 quarters · filed 2024-04-09 | $297.86M 10-Q · filed 2024-04-09 | $372.96M derived: sum of 4 quarters · filed 2024-07-30 | |||
| 2022-11-30 | $117.49M 10-Q · filed 2024-01-09 | $187.57M 10-Q · filed 2024-01-09 | $262.67M derived: sum of 3 quarters · filed 2024-07-30 | $333.50M derived: sum of 4 quarters · filed 2024-07-30 | |||
| 2022-08-31 | $70.08M 10-Q · filed 2023-10-10 | $145.17M derived: sum of 2 quarters · filed 2024-07-30 | $216.00M derived: sum of 3 quarters · filed 2024-07-30 | $285.93M derived: sum of 4 quarters · filed 2024-07-30 | |||
| 2022-05-31 | $75.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $145.93M derived: sum of 2 quarters · filed 2024-07-30 | $215.85M derived: sum of 3 quarters · filed 2024-07-30 | $284.15M 10-K · filed 2024-07-30 | |||
| 2022-02-28 | $70.83M 10-Q · filed 2023-04-04 | $140.75M derived: sum of 2 quarters · filed 2023-04-04 | $209.05M 10-Q · filed 2023-04-04 | $278.79M derived: sum of 4 quarters · filed 2023-08-15 | |||
| 2021-11-30 | $69.92M 10-Q · filed 2023-01-09 | $138.22M 10-Q · filed 2023-01-09 | $207.95M derived: sum of 3 quarters · filed 2023-08-15 | $270.81M derived: sum of 4 quarters · filed 2023-08-15 | |||
| 2021-08-31 | $68.30M 10-Q · filed 2022-09-30 | $138.03M derived: sum of 2 quarters · filed 2023-08-15 | $200.89M derived: sum of 3 quarters · filed 2023-08-15 | $262.68M derived: sum of 4 quarters · filed 2023-08-15 | |||
| 2021-05-31 | $69.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-15 | $132.59M derived: sum of 2 quarters · filed 2023-08-15 | $194.38M derived: sum of 3 quarters · filed 2023-08-15 | $253.40M 10-K · filed 2023-08-15 | |||
| 2021-02-28 | $62.86M 10-Q · filed 2022-04-01 | $124.65M derived: sum of 2 quarters · filed 2022-04-01 | $183.67M 10-Q · filed 2022-04-01 | $241.01M derived: sum of 4 quarters · filed 2022-07-27 | |||
| 2020-11-30 | $61.79M 10-Q · filed 2021-12-30 | $120.81M 10-Q · filed 2021-12-30 | $178.15M derived: sum of 3 quarters · filed 2022-07-27 | $232.69M derived: sum of 4 quarters · filed 2022-07-27 | |||
| 2020-08-31 | $59.02M 10-Q · filed 2021-09-30 | $116.37M derived: sum of 2 quarters · filed 2022-07-27 | $170.91M derived: sum of 3 quarters · filed 2022-07-27 | $227.68M derived: sum of 4 quarters · filed 2022-07-27 | |||
| 2020-05-31 | $57.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-27 | $111.88M derived: sum of 2 quarters · filed 2022-07-27 | $168.66M derived: sum of 3 quarters · filed 2022-07-27 | $221.89M 10-K · filed 2022-07-27 | |||
| 2020-02-29 | $54.54M 10-Q · filed 2021-03-31 | $111.32M derived: sum of 2 quarters · filed 2021-03-31 | $164.55M 10-Q · filed 2021-03-31 | $223.78M derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2019-11-30 | $56.78M 10-Q · filed 2020-12-29 | $110.01M 10-Q · filed 2020-12-29 | $169.24M derived: sum of 3 quarters · filed 2021-07-30 | $222.31M derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2019-08-31 | $53.23M 10-Q · filed 2020-09-30 | $112.46M derived: sum of 2 quarters · filed 2021-07-30 | $165.53M derived: sum of 3 quarters · filed 2021-07-30 | $222.60M derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2019-05-31 | $59.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-30 | $112.30M derived: sum of 2 quarters · filed 2021-07-30 | $169.37M derived: sum of 3 quarters · filed 2021-07-30 | $222.27M 10-K · filed 2021-07-30 | |||
| 2019-02-28 | $53.07M 10-Q · filed 2020-04-03 | $110.14M derived: sum of 2 quarters · filed 2020-04-03 | $163.03M 10-Q · filed 2020-04-03 | $222.66M derived: sum of 4 quarters · filed 2020-07-30 | |||
| 2018-11-30 | $57.06M 10-Q · filed 2018-12-28 | $109.96M 10-Q · filed 2019-12-27 | $169.58M derived: sum of 3 quarters · filed 2020-07-30 | $219.88M derived: sum of 4 quarters · filed 2020-07-30 | |||
| 2018-08-31 | $52.90M 10-Q · filed 2019-09-26 | $112.52M derived: sum of 2 quarters · filed 2020-07-30 | $162.82M derived: sum of 3 quarters · filed 2020-07-30 | $215.27M derived: sum of 4 quarters · filed 2020-07-30 | |||
| 2018-05-31 | $59.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-30 | $109.92M derived: sum of 2 quarters · filed 2020-07-30 | $162.37M derived: sum of 3 quarters · filed 2020-07-30 | $211.66M 10-K · filed 2020-07-30 | $212.00M 10-K · filed 2018-07-27 | ||
| 2018-02-28 | $50.30M 10-Q · filed 2019-03-29 | $102.75M derived: sum of 2 quarters · filed 2019-03-29 | $152.04M 10-Q · filed 2019-03-29 | $152.04M 10-Q · filed 2018-10-05 | |||
| 2017-11-30 | $52.45M 10-Q · filed 2018-12-28 | $101.73M 10-Q · filed 2018-12-28 | |||||
| 2017-08-31 | $49.28M 10-Q · filed 2018-10-05 | ||||||
| 2017-05-31 | $189.35M 10-K · filed 2019-07-30 | $189.63M 10-K · filed 2018-07-27 | |||||
| 2016-05-31 | $168.21M 10-K · filed 2018-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |